Pharmafile Logo

News and Press Releases

Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis 

The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan (HRCT) imaging biomarkers as a co-primary endpoint 20 January...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 20, 2026

Brainomix
investors@brainomix.com
First Floor, Seacourt Tower West Way Oxford OX2 0JJ

Exciva raises €51 million ($59m) in Series B funding round co-led by Gimv and EQT

20 January 2026 -- Heidelberg, Germany -- Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59m)...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 20, 2026

Exciva
info@exciva.com
Hauptstrasse 25, 69117 Heidelberg, Germany

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Issued and pending claims expected to protect ALTO-207 into the mid-2040s 14 January 2026 -- California, US -- Alto Neuroscience, Inc, a clinical-stage biopharmaceutical company focused on the development of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2026

Alto Neuroscience
info@altoneuroscience.com
650 Castro Street, Suite 450 Mountain View, CA 94041

Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

New patent based on treatment of populations identified to be particularly responsive to ondansetron treatment after examination of Adial’s clinical data and information 14 January 2026 -- Virginia, US --...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2026

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent

EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being investigated in Newron’s global ENIGMA-TRS Phase III development program, enrolling...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 6, 2026

Newron Pharmaceuticals
info@newron.com
via Antonio Meucci 3 20091 Bresso (Mi) Italy

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis

5 January 2026 -- California and Massachusetts, US -- MapLight Therapeutics, Inc today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 5, 2026

MapLight Therapeutics
info@maplightrx.com
800 Chesapeake Drive, Redwood City, California 9406

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Company to seek FDA alignment on global Phase 3 program replicating Phase 2b design Phase 3 initiation targeted...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 5, 2026

GH Research
info@ghres.com
Joshua Dawson House Dawson Street Dublin 2, D02 RY95 Ireland

New collaborative strategy platform launches to empower biopharma teams to reach peak sales faster and with greater confidence

11 November 2025 -- London, UK -- In a drug development landscape defined by shifting policies, geopolitical uncertainty, and increasing competitive pressure, a new collaborative strategy platform, Nmblr, has launched to empower...

Category: Biotechnology, Drug Discovery, Logistics, Other, Pharmaceutical
Posted: November 11, 2025

Nmblr

BIO-Europe 2025

10 July 2025 -- Vienna, Austria -- BIO-Europe, Europe's premier biopharma partnering event, is heading to Vienna, Austria on November 3-5, 2025, followed by Digital Partnering on November 11-12. Drawing...

Category: BioManufacturing, Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 10, 2025

BIO-Europe 2025
EBDcustomerservice@ebdgroup.com

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

1 May 2025 -- London, UK and New York, US -- OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 1, 2025

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

PLL Therapeutics enrolls first patient in phase I/II trial of drug candidate PLL001 for Amyotrophic Lateral Sclerosis (ALS)

Multi-stage Australian study will evaluate safety of PLL001 in 12 ALS patients, testing three different doses along with placebo 140 ALS patients will participate in second stage of study to...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 15, 2025

PLL Therapeutics
contact@pll-therapeutics.com
10 Avenue Roger Lapébie 33140 Villenave d’Ornon France

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability Urcosimod stable in single-use ampoules for more than 2½ years FDA requires drug to show...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 31, 2025

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front....

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Rentschler Biopharma announces strategic realignment of its global business operations

30 January 2025 – Laupheim, Germany – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations...

Category: BioManufacturing
Posted: January 30, 2025

Rentschler Biopharma
info@rentschler-biopharma.com
Erwin-Rentschler-Str. 21 88471 Laupheim Germany

Advarra Introduces Comprehensive Solution to Accelerate Study Startup and Improve Collaboration on Trials

Proven technology powers end-to-end solution designed to streamline site activation workflows, improve engagement, and optimize visibility among trial stakeholders 21 January 2025 -- Maryland, US -- Advarra, the market leader...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: January 21, 2025

Advarra
6100 Merriweather Dr., Suite 600 Columbia, MD 21044